메뉴 건너뛰기




Volumn 18, Issue 19, 2012, Pages 2702-2712

Novel VEGF-independent strategies targeting tumor vasculature: Clinical aspects

Author keywords

Angiopoietins inhibitors; Multikinase inhibitors; PDGF and FGF family; Targeting tumor vasculature; Vascular disrupting agents; VEGF independent strategies

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; ANTINEOPLASTIC AGENT; CAPECITABINE; CE 245677; CEP 11981; COMBRETASTATIN A4 PHOSPHATE; CVX 060; DOLOSTATIN 10; DOXORUBICIN; IXABEPILONE; MOTESANIB; NAVELBINE; NINTEDANIB; OMBRABULIN; PACLITAXEL; PAZOPANIB; PHOSPHOTRANSFERASE INHIBITOR; PINABULIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SORAFENIB; SUNITINIB; TREBANANIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VADIMEZAN; VASCULAR TARGETING AGENT; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VATALANIB;

EID: 84862514521     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212800626184     Document Type: Review
Times cited : (9)

References (136)
  • 1
    • 0036782278 scopus 로고    scopus 로고
    • VEGF and the quest for tumour angiogenesis factors
    • Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002; 2: 795-803.
    • (2002) Nat Rev Cancer , vol.2 , pp. 795-803
    • Ferrara, N.1
  • 2
    • 26644471951 scopus 로고    scopus 로고
    • Drug resistance by evasion of antiangiogenic, targeting of VEGF signaling in latestage pancreatic islet tumors
    • Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic, targeting of VEGF signaling in latestage pancreatic islet tumors. Cancer Cell 2005; 8: 299-309.
    • (2005) Cancer Cell , vol.8 , pp. 299-309
    • Casanovas, O.1    Hicklin, D.J.2    Bergers, G.3    Hanahan, D.4
  • 3
    • 70349807690 scopus 로고    scopus 로고
    • Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance
    • Cao Y, Zhong W, Sun Y. Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance. Semin Cancer Biol 2009; 19: 338-43.
    • (2009) Semin Cancer Biol , vol.19 , pp. 338-343
    • Cao, Y.1    Zhong, W.2    Sun, Y.3
  • 4
    • 0035906856 scopus 로고    scopus 로고
    • 3D microvascular architecture of precancerous lesions and invasive carcinomas of the colon
    • Konerding MA, Fait E, Gaumann A. 3D microvascular architecture of precancerous lesions and invasive carcinomas of the colon. Br J Cancer 2001; 84: 1354-62.
    • (2001) Br J Cancer , vol.84 , pp. 1354-1362
    • Konerding, M.A.1    Fait, E.2    Gaumann, A.3
  • 5
    • 0029948108 scopus 로고    scopus 로고
    • Microvascular studies on the origins of perfusion-limited hypoxia
    • Dewhirst MW, Kimura H, Rehmus S, et al. Microvascular studies on the origins of perfusion-limited hypoxia. Br J Cancer 1996; 27: S247-51.
    • (1996) Br J Cancer , vol.27 , pp. 247-251
    • Dewhirst, M.W.1    Kimura, H.2    Rehmus, S.3
  • 6
    • 0038376001 scopus 로고    scopus 로고
    • Imaging of angiogenesis: From microscope to clinic
    • McDonald D, Choyke P. Imaging of angiogenesis: from microscope to clinic. Nature Med 2003; 9: 713-25.
    • (2003) Nature Med , vol.9 , pp. 713-725
    • McDonald, D.1    Choyke, P.2
  • 7
    • 0034648765 scopus 로고    scopus 로고
    • Angiogenesis in cancer and other diseases
    • Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.
    • (2000) Nature , vol.407 , pp. 249-257
    • Carmeliet, P.1    Jain, R.K.2
  • 8
    • 0037223555 scopus 로고    scopus 로고
    • Tumor vessel development and maturation impose limits on the effectiveness of antivascular therapy
    • Gee MS, Procopio WN, Makonnen S, et al. Tumor vessel development and maturation impose limits on the effectiveness of antivascular therapy. Am J Pathol 2003; 162: 183-93.
    • (2003) Am J Pathol , vol.162 , pp. 183-193
    • Gee, M.S.1    Procopio, W.N.2    Makonnen, S.3
  • 9
    • 0017256549 scopus 로고
    • Increased cell killing by metronidazole and nitrofurazone of hypoxic compared to aerobic mammalian cells
    • Mohindra J, Rauth A. Increased cell killing by metronidazole and nitrofurazone of hypoxic compared to aerobic mammalian cells. Cancer Res 1976; 36: 930-6.
    • (1976) Cancer Res , vol.36 , pp. 930-936
    • Mohindra, J.1    Rauth, A.2
  • 10
    • 0347419309 scopus 로고    scopus 로고
    • Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumors under normoxic and hypoxic conditions in vitro
    • Koch S, Meyer F, Honecker F, et al. Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumors under normoxic and hypoxic conditions in vitro. Br J Cancer 2003; 89: 2133-9.
    • (2003) Br J Cancer , vol.89 , pp. 2133-2139
    • Koch, S.1    Meyer, F.2    Honecker, F.3
  • 12
    • 26944437515 scopus 로고    scopus 로고
    • PDGFR + perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival
    • Song S, Ewald AJ, Stallcup W, et al. PDGFR + perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nature Cell Biol 2005; 7: 870-9.
    • (2005) Nature Cell Biol , vol.7 , pp. 870-879
    • Song, S.1    Ewald, A.J.2    Stallcup, W.3
  • 13
    • 61649100307 scopus 로고    scopus 로고
    • The FGF family: Biology, pathophysiology and therapy
    • Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nature Rev Drug Discov 2009; 8: 235-53.
    • (2009) Nature Rev Drug Discov , vol.8 , pp. 235-253
    • Beenken, A.1    Mohammadi, M.2
  • 14
    • 78349298645 scopus 로고    scopus 로고
    • Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: A randomized trial
    • Abou-Alfa GK, Johnson P, Knox JJ, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010; 304: 2154-60.
    • (2010) JAMA , vol.304 , pp. 2154-2160
    • Abou-Alfa, G.K.1    Johnson, P.2    Knox, J.J.3
  • 15
    • 77954574658 scopus 로고    scopus 로고
    • Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203
    • Sun W, Powell M, O'Dwyer PJ, et al. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 2010; 28: 2947-51.
    • (2010) J Clin Oncol , vol.28 , pp. 2947-2951
    • Sun, W.1    Powell, M.2    O'Dwyer, P.J.3
  • 16
    • 77952468875 scopus 로고    scopus 로고
    • Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer
    • Lam ET, Ringel MD, Kloos RT, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010; 28: 2323-30.
    • (2010) J Clin Oncol , vol.28 , pp. 2323-2330
    • Lam, E.T.1    Ringel, M.D.2    Kloos, R.T.3
  • 17
    • 70149087258 scopus 로고    scopus 로고
    • Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer
    • Bianchi G, Loibl S, Zamagni C, et al. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs 2009; 20: 616-24.
    • (2009) Anticancer Drugs , vol.20 , pp. 616-624
    • Bianchi, G.1    Loibl, S.2    Zamagni, C.3
  • 18
    • 78650084078 scopus 로고    scopus 로고
    • A front-line window of opportunity phase 2 study of sorafenib in patients with advanced non-small cell lung cancer: North Central Cancer Treatment Group Study N0326
    • Dy GK, Hillman SL, Rowland KM Jr, et al. A front-line window of opportunity phase 2 study of sorafenib in patients with advanced non-small cell lung cancer: North Central Cancer Treatment Group Study N0326. Cancer 2010; 116: 5686-93.
    • (2010) Cancer , vol.116 , pp. 5686-5693
    • Dy, G.K.1    Hillman, S.L.2    Rowland Jr., K.M.3
  • 19
    • 79951988792 scopus 로고    scopus 로고
    • Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: A gynecologic oncology group trial
    • Matei D, Sill MW, Lankes HA, et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol 2011; 29: 69-75.
    • (2011) J Clin Oncol , vol.29 , pp. 69-75
    • Matei, D.1    Sill, M.W.2    Lankes, H.A.3
  • 20
    • 74249098818 scopus 로고    scopus 로고
    • Sorafenib in patients with advanced biliary tract carcinoma: A phase II trial
    • Bengala C, Bertolini F, Malavasi N, et al. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer 2010; 102: 68-72.
    • (2010) Br J Cancer , vol.102 , pp. 68-72
    • Bengala, C.1    Bertolini, F.2    Malavasi, N.3
  • 21
    • 77954754601 scopus 로고    scopus 로고
    • Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420
    • Williamson SK, Moon J, Huang CH, et al. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. J Clin Oncol 2010; 28: 3330-35.
    • (2010) J Clin Oncol , vol.28 , pp. 3330-3335
    • Williamson, S.K.1    Moon, J.2    Huang, C.H.3
  • 22
    • 77949337347 scopus 로고    scopus 로고
    • A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: A trial of the Chicago, PMH, and California Phase II Consortia
    • Nimeiri HS, Oza AM, Morgan RJ, et al. A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol. 2010; 117: 37-40.
    • (2010) Gynecol Oncol , vol.117 , pp. 37-40
    • Nimeiri, H.S.1    Oza, A.M.2    Morgan, R.J.3
  • 23
    • 42949148257 scopus 로고    scopus 로고
    • Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
    • Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. Clin Oncol 2008; 26: 1810-16.
    • (2008) Clin Oncol , vol.26 , pp. 1810-1816
    • Burstein, H.J.1    Elias, A.D.2    Rugo, H.S.3
  • 24
    • 77951296573 scopus 로고    scopus 로고
    • Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
    • Barrios CH, Liu MC, Lee SC, et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 2010; 121: 121-31.
    • (2010) Breast Cancer Res Treat , vol.121 , pp. 121-131
    • Barrios, C.H.1    Liu, M.C.2    Lee, S.C.3
  • 26
    • 39149120621 scopus 로고    scopus 로고
    • Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer
    • Socinski MA, Novello S, Brahmer JR, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008; 26: 650-66.
    • (2008) J Clin Oncol , vol.26 , pp. 650-666
    • Socinski, M.A.1    Novello, S.2    Brahmer, J.R.3
  • 27
    • 70350569370 scopus 로고    scopus 로고
    • Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study
    • Hensley ML, Sill MW, Scribner DR Jr, et al. Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol. 2009; 115: 460-5.
    • (2009) Gynecol Oncol , vol.115 , pp. 460-465
    • Hensley, M.L.1    Sill, M.W.2    Scribner Jr., D.R.3
  • 28
    • 79251585977 scopus 로고    scopus 로고
    • A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: An NCIC Clinical Trials Group Study
    • Biagi JJ, Oza AM, Chalchal HI, et al. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Ann Oncol 2011; 22: 335-40.
    • (2011) Ann Oncol , vol.22 , pp. 335-340
    • Biagi, J.J.1    Oza, A.M.2    Chalchal, H.I.3
  • 29
    • 74249122456 scopus 로고    scopus 로고
    • A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184
    • Mackay HJ, Tinker A, Winquist E, et al. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. Gynecol Oncol 2010; 116: 163-7.
    • (2010) Gynecol Oncol , vol.116 , pp. 163-167
    • Mackay, H.J.1    Tinker, A.2    Winquist, E.3
  • 30
    • 73949143686 scopus 로고    scopus 로고
    • Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01
    • Machiels JP, Henry S, Zanetta S, et al. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol 2010; 28: 21-8.
    • (2010) J Clin Oncol , vol.28 , pp. 21-28
    • Machiels, J.P.1    Henry, S.2    Zanetta, S.3
  • 31
    • 77957359933 scopus 로고    scopus 로고
    • Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: Results of a phase 2 consortium study
    • Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol. 2010; 11: 962-72.
    • (2010) Lancet Oncol , vol.11 , pp. 962-972
    • Bible, K.C.1    Suman, V.J.2    Molina, J.R.3
  • 32
    • 77956842743 scopus 로고    scopus 로고
    • A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: A trial of the Princess Margaret Hospital phase II consortium
    • Taylor SK, Chia S, Dent S, et al. A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium. Oncologist 2010; 15: 810-8.
    • (2010) Oncologist , vol.15 , pp. 810-818
    • Taylor, S.K.1    Chia, S.2    Dent, S.3
  • 33
    • 77955874058 scopus 로고    scopus 로고
    • Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer
    • Monk BJ, Mas Lopez L, Zarba JJ, et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol. 2010; 28: 3562-69.
    • (2010) J Clin Oncol , vol.28 , pp. 3562-3569
    • Monk, B.J.1    Mas, L.L.2    Zarba, J.J.3
  • 34
    • 77956649079 scopus 로고    scopus 로고
    • A Phase II, openlabel study evaluating pazopanib in patients with recurrent ovarian cancer
    • Friedlander M, Hancock KC, Rischin D, et al. A Phase II, openlabel study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 2010; 119: 32-7.
    • (2010) Gynecol Oncol , vol.119 , pp. 32-37
    • Friedlander, M.1    Hancock, K.C.2    Rischin, D.3
  • 35
    • 77955503066 scopus 로고    scopus 로고
    • Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer
    • Altorki N, Lane ME, Bauer T, et al. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. J Clin Oncol 2010; 28: 3131-7.
    • (2010) J Clin Oncol , vol.28 , pp. 3131-3137
    • Altorki, N.1    Lane, M.E.2    Bauer, T.3
  • 36
    • 67650337802 scopus 로고    scopus 로고
    • Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: A phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043)
    • Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009; 27: 3126-32.
    • (2009) J Clin Oncol , vol.27 , pp. 3126-3132
    • Sleijfer, S.1    Ray-Coquard, I.2    Papai, Z.3
  • 37
    • 79956297102 scopus 로고    scopus 로고
    • Randomized, placebocontrolled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma
    • Van Cutsem E, Bajetta E, Valle J, et al. Randomized, placebocontrolled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol. 2011; 29: 2004-10.
    • (2011) J Clin Oncol , vol.29 , pp. 2004-2010
    • van Cutsem, E.1    Bajetta, E.2    Valle, J.3
  • 38
    • 79956334386 scopus 로고    scopus 로고
    • Randomized, placebocontrolled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma
    • Hecht JR, Trarbach T, Hainsworth JD, et al. Randomized, placebocontrolled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol 2011; 29: 1997-2003.
    • (2011) J Clin Oncol , vol.29 , pp. 1997-2003
    • Hecht, J.R.1    Trarbach, T.2    Hainsworth, J.D.3
  • 39
    • 68949108390 scopus 로고    scopus 로고
    • Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer
    • Schlumberger MJ, Elisei R, Bastholt L, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol. 2009; 27: 3794-801.
    • (2009) J Clin Oncol , vol.27 , pp. 3794-3801
    • Schlumberger, M.J.1    Elisei, R.2    Bastholt, L.3
  • 40
    • 79953196070 scopus 로고    scopus 로고
    • Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A phase 2, randomised, double-blind, placebo-controlled study
    • Martin M, Roche H, Pinter T, et al. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 2011; 12: 369-76.
    • (2011) Lancet Oncol , vol.12 , pp. 369-376
    • Martin, M.1    Roche, H.2    Pinter, T.3
  • 41
    • 85038465329 scopus 로고    scopus 로고
    • An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced non squamous non-small cell lung cancer
    • Scagliotti G, Vynnychenko I, Ichinose Y, et al. An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced non squamous non-small cell lung cancer. Proceedings of 2011 ASCO Annual Meeting Late Breaking Abstract number 7512.
    • Proceedings of 2011 ASCO Annual Meeting Late Breaking Abstract Number 7512
    • Scagliotti, G.1    Vynnychenko, I.2    Ichinose, Y.3
  • 42
    • 77958038695 scopus 로고    scopus 로고
    • Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors
    • Okamoto I, Kaneda H, Satoh T, et al. Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. Mol Cancer Ther 2010; 9: 2825-33.
    • (2010) Mol Cancer Ther , vol.9 , pp. 2825-2833
    • Okamoto, I.1    Kaneda, H.2    Satoh, T.3
  • 43
    • 80053561888 scopus 로고    scopus 로고
    • Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer
    • Aug 22 [Epub ahead of print
    • Ledermann JA, Hackshaw A, Kaye S, et al. Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer. J Clin Oncol 2011; Aug 22 [Epub ahead of print]
    • (2011) J Clin Oncol
    • Ledermann, J.A.1    Hackshaw, A.2    Kaye, S.3
  • 44
    • 79957452054 scopus 로고    scopus 로고
    • A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer
    • Reck M, Kaiser R, Eschbach C, et al. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol 2011; 22: 1374-81.
    • (2011) Ann Oncol , vol.22 , pp. 1374-1381
    • Reck, M.1    Kaiser, R.2    Eschbach, C.3
  • 45
    • 33750513160 scopus 로고    scopus 로고
    • Interaction between Tie receptors modulates angiogenic activity of angiopoietin2 in endothelial progenitor cells
    • Kim KL, Shin IS, Kim JM, et al. Interaction between Tie receptors modulates angiogenic activity of angiopoietin2 in endothelial progenitor cells. Cardiovasc Res 2006; 72: 394-402.
    • (2006) Cardiovasc Res , vol.72 , pp. 394-402
    • Kim, K.L.1    Shin, I.S.2    Kim, J.M.3
  • 46
    • 0038374813 scopus 로고    scopus 로고
    • Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma
    • Mitsuhashi, N. Shimizu H, Ohtsuka M, et al. Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology 2003; 37: 1105-13.
    • (2003) Hepatology , vol.37 , pp. 1105-1113
    • Mitsuhashi, N.1    Shimizu, H.2    Ohtsuka, M.3
  • 47
    • 0035866389 scopus 로고    scopus 로고
    • The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer
    • Ahmad SA, Liu W, Jung YD, et al. The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. Cancer Res 2001; 61: 1255-9.
    • (2001) Cancer Res , vol.61 , pp. 1255-1259
    • Ahmad, S.A.1    Liu, W.2    Jung, Y.D.3
  • 48
    • 0037428670 scopus 로고    scopus 로고
    • Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival
    • Sfiligoi C, de Luca A, Cascone I, et al. Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival. Int. J Cancer 2003; 103: 466-74.
    • (2003) Int. J Cancer , vol.103 , pp. 466-474
    • Sfiligoi, C.1    de Luca, A.2    Cascone, I.3
  • 49
    • 0034045741 scopus 로고    scopus 로고
    • The angiopoietins, tie2 and vascular endothelial growth factor are differentially expressed in the transformation of normal lung to non-small cell lung carcinomas
    • Wong MP, Chan SY, Fu KH, et al. The angiopoietins, tie2 and vascular endothelial growth factor are differentially expressed in the transformation of normal lung to non-small cell lung carcinomas. Lung Cancer 2000; 29: 11-22.
    • (2000) Lung Cancer , vol.29 , pp. 11-22
    • Wong, M.P.1    Chan, S.Y.2    Fu, K.H.3
  • 50
    • 13544251726 scopus 로고    scopus 로고
    • Angiopoietin 2 expression is related to histological grade, vascular density, metastases, and outcome in prostate cancer
    • Lind AJ, Wikström P, Granfors T, et al. Angiopoietin 2 expression is related to histological grade, vascular density, metastases, and outcome in prostate cancer. Prostate 2005; 62: 394-9.
    • (2005) Prostate , vol.62 , pp. 394-399
    • Lind, A.J.1    Wikström, P.2    Granfors, T.3
  • 51
    • 1842582434 scopus 로고    scopus 로고
    • Expression of the angopoietin-1, angopoietin-2, Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer
    • Hata K, Nakayama K, Fujiwaki R, et al. Expression of the angopoietin-1, angopoietin-2, Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer. Gynecol Oncol 2004; 93: 215-22.
    • (2004) Gynecol Oncol , vol.93 , pp. 215-222
    • Hata, K.1    Nakayama, K.2    Fujiwaki, R.3
  • 52
    • 58149394474 scopus 로고    scopus 로고
    • Discontinued drugs in 2007: Oncology drugs
    • Williams R. Discontinued drugs in 2007: oncology drugs. Expert Opin Investig Drugs 2008; 17: 1791-816.
    • (2008) Expert Opin Investig Drugs , vol.17 , pp. 1791-1816
    • Williams, R.1
  • 53
    • 85038469660 scopus 로고    scopus 로고
    • Available at, Last accessed 17 October
    • Cephalon Oncology Pipeline. Available at: http://82.97.9.35/cephalon/Portals/0/pdf/Cephalon%20Oncology%20Pipeline.pdf [Last accessed 17 October 2011]
    • (2011) Cephalon Oncology Pipeline
  • 54
    • 0033753903 scopus 로고    scopus 로고
    • Expression and function of angiopoietin-1 in breast cancer
    • Hayes AJ, Huang WQ, Yu J, et al. Expression and function of angiopoietin-1 in breast cancer. Br J Cancer 2000; 83: 1154-60.
    • (2000) Br J Cancer , vol.83 , pp. 1154-1160
    • Hayes, A.J.1    Huang, W.Q.2    Yu, J.3
  • 55
    • 0038407310 scopus 로고    scopus 로고
    • Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors
    • Stoeltzing O, Ahmad SA, Liu W, et al. Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. Cancer Res 2003; 63: 3370-7.
    • (2003) Cancer Res , vol.63 , pp. 3370-3377
    • Stoeltzing, O.1    Ahmad, S.A.2    Liu, W.3
  • 56
    • 0036112626 scopus 로고    scopus 로고
    • Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth
    • Hawighorst T, Skobe M, Streit M, et al. Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth. Am J Pathol 2002; 160: 1381-92.
    • (2002) Am J Pathol , vol.160 , pp. 1381-1392
    • Hawighorst, T.1    Skobe, M.2    Streit, M.3
  • 57
    • 77958042477 scopus 로고    scopus 로고
    • Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: Implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody
    • Coxon A, Bready J, Min H, et al. Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol Cancer Ther 2010; 9: 2641-51.
    • (2010) Mol Cancer Ther , vol.9 , pp. 2641-2651
    • Coxon, A.1    Bready, J.2    Min, H.3
  • 58
    • 70249114453 scopus 로고    scopus 로고
    • Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors
    • Herbst RS, Hong D, Chap L, et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 2009; 27: 3557-65.
    • (2009) J Clin Oncol , vol.27 , pp. 3557-3565
    • Herbst, R.S.1    Hong, D.2    Chap, L.3
  • 59
    • 77953097101 scopus 로고    scopus 로고
    • Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors
    • Mita AC, Takimoto CH, Mita M, et al. Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res 2010; 16: 3044-56.
    • (2010) Clin Cancer Res , vol.16 , pp. 3044-3056
    • Mita, A.C.1    Takimoto, C.H.2    Mita, M.3
  • 60
    • 85038460749 scopus 로고    scopus 로고
    • Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian carcinoma
    • Karlan BY, Oza AM, Hansen VL, et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian carcinoma. Proceedings of 2010 ASCO Annual Meeting Abstract number 5000.
    • Proceedings of 2010 ASCO Annual Meeting Abstract Number 5000
    • Karlan, B.Y.1    Oza, A.M.2    Hansen, V.L.3
  • 62
    • 85038472745 scopus 로고    scopus 로고
    • AMG 386 in combination with sorafenib in patients with metastatic renal cell cancer: A randomized, double-blind, placebo-controlled, phase II study
    • Rini BI, Szczylik C, Tannir NM, et al. AMG 386 in combination with sorafenib in patients with metastatic renal cell cancer: a randomized, double-blind, placebo-controlled, phase II study. Proceedings of 2011 ASCO Annual Meeting Abstract number 309.
    • Proceedings of 2011 ASCO Annual Meeting Abstract Number 309
    • Rini, B.I.1    Szczylik, C.2    Tannir, N.M.3
  • 63
    • 85038470406 scopus 로고    scopus 로고
    • A randomized, placebocontrolled phase II study of AMG 386 plus bevacizumab and paclitaxel or AMG 386 plus paclitaxel as first-line therapy in patients with HER2-negative, locally recurrent or metastatic breast cancer
    • Dieras V, Jassem J, Dirix LY, et al. A randomized, placebocontrolled phase II study of AMG 386 plus bevacizumab and paclitaxel or AMG 386 plus paclitaxel as first-line therapy in patients with HER2-negative, locally recurrent or metastatic breast cancer. Proceedings of 2011 ASCO Annual Meeting Abstract number 544.
    • Proceedings of 2011 ASCO Annual Meeting Abstract Number 544
    • Dieras, V.1    Jassem, J.2    Dirix, L.Y.3
  • 64
    • 85038461624 scopus 로고    scopus 로고
    • Randomized, doubleblind, placebo-controlled phase II study of AMG 386 in combination with cisplatin and capecitabine in patients with metastatic gastroesophageal adenocarcinoma
    • Eatock MM, Szanto J, Tebbutt NC, et al. Randomized, doubleblind, placebo-controlled phase II study of AMG 386 in combination with cisplatin and capecitabine in patients with metastatic gastroesophageal adenocarcinoma. Proceedings of 2005 ASCO Annual Meeting Abstract number 66.
    • Proceedings of 2005 ASCO Annual Meeting Abstract Number 66
    • Eatock, M.M.1    Szanto, J.2    Tebbutt, N.C.3
  • 65
    • 85038456697 scopus 로고    scopus 로고
    • Exposure-response relationships of AMG 386 in combination with weekly paclitaxel in advanced ovarian cancer: Population pharmacokinetic/pharmacodynamic modeling to facilitate phase III dose selection
    • Lu J, Rasmussen E, Navale L, et al. Exposure-response relationships of AMG 386 in combination with weekly paclitaxel in advanced ovarian cancer: Population pharmacokinetic/pharmacodynamic modeling to facilitate phase III dose selection. Proceedings of 2010 ASCO Annual Meeting Abstract number 5042.
    • Proceedings of 2010 ASCO Annual Meeting Abstract Number
    • Lu, J.1    Rasmussen, E.2    Navale, L.3
  • 66
    • 85038459013 scopus 로고    scopus 로고
    • First-in-human doseescalation safety and PK trial of a novel intravenous humanized monoclonal CovX body inhibiting angiopoietin-2
    • Rosen LS, Mendelson DS, Cohen RB, et al. First-in-human doseescalation safety and PK trial of a novel intravenous humanized monoclonal CovX body inhibiting angiopoietin-2. Proceedings of 2010 ASCO Annual Meeting Abstract number 2524.
    • Proceedings of 2010 ASCO Annual Meeting Abstract Number
    • Rosen, L.S.1    Mendelson, D.S.2    Cohen, R.B.3
  • 67
    • 1642352048 scopus 로고    scopus 로고
    • Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice
    • Ching LM, Zwain S, Baguley BC. Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br J Cancer 2004; 90: 906-10.
    • (2004) Br J Cancer , vol.90 , pp. 906-910
    • Ching, L.M.1    Zwain, S.2    Baguley, B.C.3
  • 68
    • 33847247311 scopus 로고    scopus 로고
    • Visualizing the acute effects of vascular-targeted therapy in vivo using intravital microscopy and magnetic resonance imaging: Correlation with endothelial apoptosis, cytokine induction, and treatment outcome
    • Seshadri M, Spernyak JA, Maiery PG, et al. Visualizing the acute effects of vascular-targeted therapy in vivo using intravital microscopy and magnetic resonance imaging: correlation with endothelial apoptosis, cytokine induction, and treatment outcome. Neoplasia 2007; 9: 128-35.
    • (2007) Neoplasia , vol.9 , pp. 128-135
    • Seshadri, M.1    Spernyak, J.A.2    Maiery, P.G.3
  • 69
    • 0037125028 scopus 로고    scopus 로고
    • Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4acetic acid
    • Ching LM, Cao Z, Kieda C, et al. Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4acetic acid. Br J Cancer 2002; 86: 1937-42.
    • (2002) Br J Cancer , vol.86 , pp. 1937-1942
    • Ching, L.M.1    Cao, Z.2    Kieda, C.3
  • 70
    • 67650485823 scopus 로고    scopus 로고
    • Neutrophil influx and chemokine production during the early phases of the antitumor response to the vascular disrupting agent DMXAA (ASA404)
    • Wang L, Thomsen L, Sutherland R, et al. Neutrophil influx and chemokine production during the early phases of the antitumor response to the vascular disrupting agent DMXAA (ASA404). Neoplasia 2009; 11: 793-803.
    • (2009) Neoplasia , vol.11 , pp. 793-803
    • Wang, L.1    Thomsen, L.2    Sutherland, R.3
  • 71
    • 0030625644 scopus 로고    scopus 로고
    • Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: Relation to vascular effects
    • Baguley BC, Zhuang L, Kestell P. Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects. Oncol Res 1997; 9: 55-60.
    • (1997) Oncol Res , vol.9 , pp. 55-60
    • Baguley, B.C.1    Zhuang, L.2    Kestell, P.3
  • 72
    • 0033565644 scopus 로고    scopus 로고
    • Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice
    • Ching LM, Goldsmith D, Joseph WR, et al. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res 1999; 59: 3304-7.
    • (1999) Cancer Res , vol.59 , pp. 3304-3307
    • Ching, L.M.1    Goldsmith, D.2    Joseph, W.R.3
  • 73
    • 0037068317 scopus 로고    scopus 로고
    • The antitumor activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice
    • Zhao L, Baguley BC, Kestell P. The antitumor activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. Br J Cancer 2002; 87: 465-70.
    • (2002) Br J Cancer , vol.87 , pp. 465-470
    • Zhao, L.1    Baguley, B.C.2    Kestell, P.3
  • 74
    • 22044437369 scopus 로고    scopus 로고
    • Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability
    • Zhao L, Ching LM, Kestell P, et al. Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability. Int J Cancer 2005; 116: 322-6.
    • (2005) Int J Cancer , vol.116 , pp. 322-326
    • Zhao, L.1    Ching, L.M.2    Kestell, P.3
  • 75
    • 33646342514 scopus 로고    scopus 로고
    • Rat tumor response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis
    • McPhail LD, McIntyre DJ, Ludwig C, et al. Rat tumor response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis. Neoplasia 2006; 8: 199-206.
    • (2006) Neoplasia , vol.8 , pp. 199-206
    • McPhail, L.D.1    McIntyre, D.J.2    Ludwig, C.3
  • 76
    • 1042263997 scopus 로고    scopus 로고
    • Induction of tumour necrosis factor and interferon-gamma in cultured murine splenocytes by the antivascular agent DMXAA and its metabolites
    • Wang LC, Reddy CB, Baguley BC, et al. Induction of tumour necrosis factor and interferon-gamma in cultured murine splenocytes by the antivascular agent DMXAA and its metabolites. Biochem Pharmacol 2004; 67: 937-45.
    • (2004) Biochem Pharmacol , vol.67 , pp. 937-945
    • Wang, L.C.1    Reddy, C.B.2    Baguley, B.C.3
  • 77
    • 0033083206 scopus 로고    scopus 로고
    • Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: A novel approach to cancer therapy
    • Joseph WR, Cao Z, Mountjoy KG, Marshall ES, Baguley BC, Ching LM. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. Cancer Res. 1999; 59: 633-8.
    • (1999) Cancer Res , vol.59 , pp. 633-638
    • Joseph, W.R.1    Cao, Z.2    Mountjoy, K.G.3    Marshall, E.S.4    Baguley, B.C.5    Ching, L.M.6
  • 78
    • 74549118938 scopus 로고    scopus 로고
    • The development of the tumor vasculardisrupting agent ASA404 (vadimezan, DMXAA): Current status and future opportunities
    • Head M, Jameson MB. The development of the tumor vasculardisrupting agent ASA404 (vadimezan, DMXAA): Current status and future opportunities. Expert Opin Investig Drugs 2010; 19: 295-304.
    • (2010) Expert Opin Investig Drugs , vol.19 , pp. 295-304
    • Head, M.1    Jameson, M.B.2
  • 79
    • 84862572180 scopus 로고    scopus 로고
    • Consistent marked potentiation of the in vivo antitumor activity of taxanes by the vascular disrupting agent, DMXAA, in lung, ovarian and prostate cancer xenografts
    • Washington, DC, April 1-6, abstr 514
    • Green C, Djeha H, Ireson C, et al. Consistent marked potentiation of the in vivo antitumor activity of taxanes by the vascular disrupting agent, DMXAA, in lung, ovarian and prostate cancer xenografts. Proceedings of the Annual Meeting of the American Association of Cancer Research, Washington, DC, April 1-6, 2006 (abstr 514).
    • (2006) Proceedings of the Annual Meeting of the American Association of Cancer Research
    • Green, C.1    Djeha, H.2    Ireson, C.3
  • 80
    • 0037222218 scopus 로고    scopus 로고
    • Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
    • Siim BG, Lee AE, Shalal-Zwain S, et al. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 2003; 51: 43-52.
    • (2003) Cancer Chemother Pharmacol , vol.51 , pp. 43-52
    • Siim, B.G.1    Lee, A.E.2    Shalal-Zwain, S.3
  • 81
    • 79952762340 scopus 로고    scopus 로고
    • Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer
    • Hida T, Tamiya M, Nishio M, et al. Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer. Cancer Sci 2011; 102: 845-51.
    • (2011) Cancer Sci , vol.102 , pp. 845-851
    • Hida, T.1    Tamiya, M.2    Nishio, M.3
  • 82
    • 57449103348 scopus 로고    scopus 로고
    • Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer
    • McKeage MJ, Von Pawel J, Reck M, et al. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 2008; 99: 2006-12.
    • (2008) Br J Cancer , vol.99 , pp. 2006-2012
    • McKeage, M.J.1    von Pawel, J.2    Reck, M.3
  • 84
    • 80051638135 scopus 로고    scopus 로고
    • Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer
    • Lara PN Jr, Douillard JY, Nakagawa K, et al. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol 2011; 29: 2965-71.
    • (2011) J Clin Oncol , vol.29
    • Lara, P.N.1    Douillard, J.Y.2    Nakagawa, K.3
  • 86
    • 0035064594 scopus 로고    scopus 로고
    • Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo
    • Galbraith SM, Chaplin DJ, Lee F, et al. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res 2001; 21: 93-102.
    • (2001) Anticancer Res , vol.21 , pp. 93-102
    • Galbraith, S.M.1    Chaplin, D.J.2    Lee, F.3
  • 87
    • 0037085753 scopus 로고    scopus 로고
    • The tumor vascular targeting agent combretastatin A-4phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells
    • Kanthou C, Tozer GM. The tumor vascular targeting agent combretastatin A-4phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 2002; 99: 2060-9.
    • (2002) Blood , vol.99 , pp. 2060-2069
    • Kanthou, C.1    Tozer, G.M.2
  • 88
    • 5044223522 scopus 로고    scopus 로고
    • Therapeutic strategies that selectively target and disrupt established tumor vasculature
    • Siemann DW. Therapeutic strategies that selectively target and disrupt established tumor vasculature. Hematol Oncol Clin North Am 2004; 18: 1023-37.
    • (2004) Hematol Oncol Clin North Am , vol.18 , pp. 1023-1037
    • Siemann, D.W.1
  • 89
    • 33750504410 scopus 로고    scopus 로고
    • Morphologic manifestations of vasculardisrupting agents in preclinical models
    • In: Siemann DW, editor, London: WileyBlackwell
    • Rojiani AM, Rojiani M. Morphologic manifestations of vasculardisrupting agents in preclinical models. In: Siemann DW, editor. Vascular-Targeted Therapies in Oncology. London: WileyBlackwell; 2006. p. 81-94.
    • (2006) Vascular-Targeted Therapies In Oncology , pp. 81-94
    • Rojiani, A.M.1    Rojiani, M.2
  • 90
    • 49049097050 scopus 로고    scopus 로고
    • Small molecule vascular disrupting agents in cancer therapy
    • Ellis L, Teicher B, editors. Totowa: Humana
    • Siemann D, Horsman M. Small molecule vascular disrupting agents in cancer therapy. Antiangiogenic Agents in Cancer Therapy. In: Ellis L, Teicher B, editors. Totowa: Humana; 2008. p. 297-310.
    • (2008) Antiangiogenic Agents In Cancer Therapy , pp. 297-310
    • Siemann, D.1    Horsman, M.2
  • 91
    • 27644466314 scopus 로고    scopus 로고
    • Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling
    • Vincent L, Kermani P, Young LM, et al. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest 2005; 115: 2992-3006.
    • (2005) J Clin Invest , vol.115 , pp. 2992-3006
    • Vincent, L.1    Kermani, P.2    Young, L.M.3
  • 92
    • 65549164757 scopus 로고    scopus 로고
    • Microtubule depolymerizing vascular disrupting agents: Novel therapeutic agents for oncology and other pathologies
    • Kanthou C, Tozer GM. Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies. Int J Exp Pathol 2009; 90: 284-94.
    • (2009) Int J Exp Pathol , vol.90 , pp. 284-294
    • Kanthou, C.1    Tozer, G.M.2
  • 93
    • 0037096814 scopus 로고    scopus 로고
    • A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer
    • Dowlati A, Robertson K, Cooney M, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002; 62: 340-816.
    • (2002) Cancer Res , vol.62 , pp. 340-348
    • Dowlati, A.1    Robertson, K.2    Cooney, M.3
  • 94
    • 0642307227 scopus 로고    scopus 로고
    • Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: Magnetic resonance imaging evidence for altered tumor blood flow
    • Stevenson JP, Rosen M, Sun W, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003; 21: 4428-38.
    • (2003) J Clin Oncol , vol.21 , pp. 4428-4438
    • Stevenson, J.P.1    Rosen, M.2    Sun, W.3
  • 95
    • 0042386700 scopus 로고    scopus 로고
    • Phase I clinical trial of weekly combretastatin A4 phosphate: Clinical and pharmacokinetic results
    • Rustin GJ, Galbraith SM, Anderson H, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003; 21: 2815-22.
    • (2003) J Clin Oncol , vol.21 , pp. 2815-2822
    • Rustin, G.J.1    Galbraith, S.M.2    Anderson, H.3
  • 97
    • 0030951899 scopus 로고    scopus 로고
    • Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature
    • Dark GG, Hill SA, Prise VE, et al. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997; 57: 1829-34.
    • (1997) Cancer Res , vol.57 , pp. 1829-1834
    • Dark, G.G.1    Hill, S.A.2    Prise, V.E.3
  • 98
    • 0036215178 scopus 로고    scopus 로고
    • Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma
    • Li L, Rojiani AM, Siemann DW. Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma. Acta Oncol 2002; 41: 91-7.
    • (2002) Acta Oncol , vol.41 , pp. 91-97
    • Li, L.1    Rojiani, A.M.2    Siemann, D.W.3
  • 99
    • 0034109559 scopus 로고    scopus 로고
    • Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma
    • Grosios K, Loadman P, Swaine D, et al. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res 2000; 20: 229-33.
    • (2000) Anticancer Res , vol.20 , pp. 229-233
    • Grosios, K.1    Loadman, P.2    Swaine, D.3
  • 100
    • 0036568457 scopus 로고    scopus 로고
    • Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy
    • Siemann DW, Mercer E, Lepler S, et al. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 2002; 99: 1-6.
    • (2002) Int J Cancer , vol.99 , pp. 1-6
    • Siemann, D.W.1    Mercer, E.2    Lepler, S.3
  • 101
    • 20044395276 scopus 로고    scopus 로고
    • Phase I trial of combretastatin A-4 phosphate with carboplatin
    • Bilenker JH, Flaherty KT, Rosen M, et al. Phase I trial of combretastatin A-4 phosphate with carboplatin. Clin Cancer Res 2005; 11: 1527-33.
    • (2005) Clin Cancer Res , vol.11 , pp. 1527-1533
    • Bilenker, J.H.1    Flaherty, K.T.2    Rosen, M.3
  • 102
    • 77951667223 scopus 로고    scopus 로고
    • A phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer
    • Rustin GJ, Shreeves G, Nathan PD, et al. A phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Br J Cancer 2010; 102: 1355-60.
    • (2010) Br J Cancer , vol.102 , pp. 1355-1360
    • Rustin, G.J.1    Shreeves, G.2    Nathan, P.D.3
  • 103
    • 79953648492 scopus 로고    scopus 로고
    • Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer
    • Zweifel M, Jayson GC, Reed NS, et al. Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol 2011; 22: 2036-41.
    • (2011) Ann Oncol , vol.22 , pp. 2036-2041
    • Zweifel, M.1    Jayson, G.C.2    Reed, N.S.3
  • 104
    • 20344394640 scopus 로고    scopus 로고
    • The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors
    • Siemann DW, Rojiani AM. The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors. Int J Radiat Oncol Biol Phys 2005; 62: 846-53.
    • (2005) Int J Radiat Oncol Biol Phys , vol.62 , pp. 846-853
    • Siemann, D.W.1    Rojiani, A.M.2
  • 106
    • 84861686761 scopus 로고    scopus 로고
    • Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck
    • Jul 15, Epub ahead of print
    • Ng QS, Mandeville H, Goh V, et al. Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck. Ann Oncol 2011 Jul 15[Epub ahead of print].
    • (2011) Ann Oncol
    • Ng, Q.S.1    Mandeville, H.2    Goh, V.3
  • 108
    • 0033395393 scopus 로고    scopus 로고
    • Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy
    • Nihei Y, Suga Y, Morinaga Y, et al. Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy. Jpn J Cancer Res. 1999; 90: 1016-25.
    • (1999) Jpn J Cancer Res , vol.90 , pp. 1016-1025
    • Nihei, Y.1    Suga, Y.2    Morinaga, Y.3
  • 109
    • 84862551154 scopus 로고    scopus 로고
    • A phase I safety, pharmacokinetic and pharmacodynamic study of AVE8062, a novel vascular disrupting agent, in patients with advanced solid tumors. Proceedings of 7th TAT meeting
    • April, abstract O36
    • Sessa C, Soria JC, Tolcher A, et al. A phase I safety, pharmacokinetic and pharmacodynamic study of AVE8062, a novel vascular disrupting agent, in patients with advanced solid tumors. Proceedings of 7th TAT meeting, Amsterdam, 18-22 April 2009: abstract O36.
    • (2009) Amsterdam , pp. 18-22
    • Sessa, C.1    Soria, J.C.2    Tolcher, A.3
  • 110
    • 84933682759 scopus 로고    scopus 로고
    • A comprehensive study of translational research and safety exploration of the vascular disrupting agent (VDA) AVE8062 in combination with cisplatin administered every 3 weeks to patients with advanced solid tumors
    • CA, 12-16 April, abstract
    • Soria JC, Sessa C, Perotti A, et al. A comprehensive study of translational research and safety exploration of the vascular disrupting agent (VDA) AVE8062 in combination with cisplatin administered every 3 weeks to patients with advanced solid tumors. Proceedings of 99th AACR Annual Meeting; San Diego, CA, 12-16 April 2008; abstract 07-11.
    • (2008) Proceedings of 99th AACR Annual Meeting; San Diego , pp. 07-11
    • Soria, J.C.1    Sessa, C.2    Perotti, A.3
  • 111
    • 70349338935 scopus 로고    scopus 로고
    • AVE8062: A new combretastatin derivative vascular disrupting agent
    • Delmonte A, Sessa C. AVE8062: a new combretastatin derivative vascular disrupting agent. Expert Opin Investig Drugs. 2009; 18: 1541-8.
    • (2009) Expert Opin Investig Drugs , vol.18 , pp. 1541-1548
    • Delmonte, A.1    Sessa, C.2
  • 112
    • 18844461704 scopus 로고    scopus 로고
    • Phase II trial of dolastatin-10 in patients with advanced breast cancer
    • Perez EA, Hillman DW, Fishkin PA, et al. Phase II trial of dolastatin-10 in patients with advanced breast cancer. Invest New Drugs. 2005; 23: 257-61.
    • (2005) Invest New Drugs , vol.23 , pp. 257-261
    • Perez, E.A.1    Hillman, D.W.2    Fishkin, P.A.3
  • 113
    • 0037384048 scopus 로고    scopus 로고
    • A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology Group Study
    • Hoffman MA, Blessing JA, Lentz SS. A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology Group Study. Gynecol Oncol 2003; 89: 95-8.
    • (2003) Gynecol Oncol , vol.89 , pp. 95-98
    • Hoffman, M.A.1    Blessing, J.A.2    Lentz, S.S.3
  • 114
    • 0034093431 scopus 로고    scopus 로고
    • Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer
    • Krug LM, Miller VA, Kalemkerian GP, et al. Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer. Ann Oncol. 2000; 11: 227-8.
    • (2000) Ann Oncol , vol.11 , pp. 227-228
    • Krug, L.M.1    Miller, V.A.2    Kalemkerian, G.P.3
  • 115
    • 23844535643 scopus 로고    scopus 로고
    • Phase II trials of dolastatin10 in advanced pancreaticobiliary cancers
    • Kindler HL, Tothy PK, Wolff R, et al. Phase II trials of dolastatin10 in advanced pancreaticobiliary cancers. Invest New Drugs. 2005; 23: 489-93.
    • (2005) Invest New Drugs , vol.23 , pp. 489-493
    • Kindler, H.L.1    Tothy, P.K.2    Wolff, R.3
  • 116
    • 0036795186 scopus 로고    scopus 로고
    • Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer
    • Saad ED, Kraut EH, Hoff PM, et al. Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer. Am J Clin Oncol. 2002; 25: 451-3.
    • (2002) Am J Clin Oncol , vol.25 , pp. 451-453
    • Saad, E.D.1    Kraut, E.H.2    Hoff, P.M.3
  • 117
    • 0033739893 scopus 로고    scopus 로고
    • Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma
    • Vaishampayan U, Glode M, Du W, et al. Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma. Clin Cancer Res. 2000; 6: 4205-8.
    • (2000) Clin Cancer Res , vol.6 , pp. 4205-4208
    • Vaishampayan, U.1    Glode, M.2    Du, W.3
  • 118
    • 11244283696 scopus 로고    scopus 로고
    • Phase II Trial of Dolastatin-10, a Novel AntiTubulin Agent, in Metastatic Soft Tissue Sarcomas
    • von Mehren M, Balcerzak SP, Kraft AS, et al. Phase II Trial of Dolastatin-10, a Novel AntiTubulin Agent, in Metastatic Soft Tissue Sarcomas. Sarcoma. 2004; 8: 107-11.
    • (2004) Sarcoma , vol.8 , pp. 107-111
    • von Mehren, M.1    Balcerzak, S.P.2    Kraft, A.S.3
  • 119
    • 18844444472 scopus 로고    scopus 로고
    • Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors
    • de Jonge MJ, van der Gaast A, Planting AS, et al. Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors. Clin Cancer Res 2005; 11: 3806-13.
    • (2005) Clin Cancer Res , vol.11 , pp. 3806-3813
    • de Jonge, M.J.1    van der Gaast, A.2    Planting, A.S.3
  • 120
    • 33747894345 scopus 로고    scopus 로고
    • A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a threeweekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours
    • Greystoke A, Blagden S, Thomas AL, et al. A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a threeweekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours. Ann Oncol. 2006; 17: 1313-9.
    • (2006) Ann Oncol , vol.17 , pp. 1313-1319
    • Greystoke, A.1    Blagden, S.2    Thomas, A.L.3
  • 121
    • 33846041131 scopus 로고    scopus 로고
    • A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy
    • Riely GJ, Gadgeel S, Rothman I, et al. A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy. Lung Cancer. 2007; 55: 181-5.
    • (2007) Lung Cancer , vol.55 , pp. 181-185
    • Riely, G.J.1    Gadgeel, S.2    Rothman, I.3
  • 122
    • 33845582571 scopus 로고    scopus 로고
    • Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy
    • Patel S, Keohan ML, Saif MW, et al. Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy. Cancer 2006; 107: 2881-7.
    • (2006) Cancer , vol.107 , pp. 2881-2887
    • Patel, S.1    Keohan, M.L.2    Saif, M.W.3
  • 123
    • 67249084753 scopus 로고    scopus 로고
    • ABT-751, a novel tubulinbinding agent, decreases tumor perfusion and disrupts tumor vasculature
    • Luo Y, Hradil VP, Frost DJ, et al. ABT-751, a novel tubulinbinding agent, decreases tumor perfusion and disrupts tumor vasculature. Anticancer Drugs 2009; 20: 483-92.
    • (2009) Anticancer Drugs , vol.20 , pp. 483-492
    • Luo, Y.1    Hradil, V.P.2    Frost, D.J.3
  • 124
    • 33646741205 scopus 로고    scopus 로고
    • The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: Results of a phase 1 study
    • Hande KR, Hagey A, Berlin J, et al. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clin Cancer Res 2006; 12: 2834-40.
    • (2006) Clin Cancer Res , vol.12 , pp. 2834-2840
    • Hande, K.R.1    Hagey, A.2    Berlin, J.3
  • 126
    • 85038454118 scopus 로고    scopus 로고
    • Phase I study of ABT-751 in combination with CAPIRI (capecitabine and irinotecan) and bevacizumab in patients with advanced colorectal cancer
    • Rudek MA, Laheru D, Zhao M, et al. Phase I study of ABT-751 in combination with CAPIRI (capecitabine and irinotecan) and bevacizumab in patients with advanced colorectal cancer. Proceedings of 2006 ASCO Annual Meeting Abstract number 253.
    • Proceedings of 2006 ASCO Annual Meeting Abstract Number 253
    • Rudek, M.A.1    Laheru, D.2    Zhao, M.3
  • 127
    • 44649138596 scopus 로고    scopus 로고
    • A phase II study of ABT-751 in patients with advanced non-small cell lung cancer
    • Mauer AM, Cohen EE, Ma PC, et al. A phase II study of ABT-751 in patients with advanced non-small cell lung cancer. J Thorac Oncol 2008; 3: 631-6.
    • (2008) J Thorac Oncol , vol.3 , pp. 631-636
    • Mauer, A.M.1    Cohen, E.E.2    Ma, P.C.3
  • 132
    • 77955978648 scopus 로고    scopus 로고
    • Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent
    • Lickliter JD, Francesconi AB, Smith G, et al. Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent. Br J Cancer 2010; 103: 597-606.
    • (2010) Br J Cancer , vol.103 , pp. 597-606
    • Lickliter, J.D.1    Francesconi, A.B.2    Smith, G.3
  • 133
    • 78650376933 scopus 로고    scopus 로고
    • Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas
    • Mita MM, Spear MA, Yee LK, et al. Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas. Clin Cancer Res. 2010; 16: 5892-9.
    • (2010) Clin Cancer Res , vol.16 , pp. 5892-5899
    • Mita, M.M.1    Spear, M.A.2    Yee, L.K.3
  • 134
    • 84864345773 scopus 로고    scopus 로고
    • Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel
    • Epub ahead of print
    • Millward M, Mainwaring P, Mita A, et al. Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel. Invest New Drugs. 2011 Feb 16.[Epub ahead of print].
    • (2011) Invest New Drugs , pp. 16
    • Millward, M.1    Mainwaring, P.2    Mita, A.3
  • 136
    • 80054743497 scopus 로고    scopus 로고
    • A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors
    • Ricart AD, Ashton EA, Cooney MM, et al. A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011; 68: 959-70.
    • (2011) Cancer Chemother Pharmacol , vol.68 , pp. 959-970
    • Ricart, A.D.1    Ashton, E.A.2    Cooney, M.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.